Short-term Anterior Segment Changes After Pars Plana Vitrectomy (PPV) and Silicone Oil (SO) Tamponade, Anterior Segment OCT (AS-OCT) Study.

Launched by ASSIUT UNIVERSITY · Oct 26, 2022

Keywords

ClinConnect Summary

This clinical trial is studying how a specific eye surgery called Pars Plana Vitrectomy (PPV) and the use of silicone oil (a substance used to help the eye heal) affect the front part of the eye during the early recovery period. Researchers will use a special imaging technique called Anterior Segment Optical Coherence Tomography (AS-OCT) to look closely at changes in the eye after the surgery. The goal is to better understand how these procedures impact patients who have various eye conditions, such as retinal detachment or bleeding in the eye.

To participate in this study, patients should be dealing with specific eye problems and either have a clear natural lens or have had cataract surgery at least three months before the PPV. However, individuals with certain eye issues, like previous eye injuries or significant cataracts that need to be treated at the same time, won't be eligible. If someone joins the study, they can expect to undergo the surgery and then have their eyes monitored closely for any changes in the weeks following the procedure. This research aims to improve the understanding of recovery from these surgeries and ultimately help patients heal better.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients suffering from different vitreo-retinal disorders (rhegmatogenous retinal detachment, diabetic vitreous hemorrhage, diabetic tractional retinal detachment) with either preserved crystalline lens or previous cataract surgery (at least 3 months prior to PPV) will be recruited
• Exclusion Criteria:
• • Patient with previous history of ocular trauma, co-existing glaucoma, co-existing anterior uveitis, complicated cataract surgery, IOL-related complications, previous vitreo-retinal surgery, visually significant cataract (necessitating combined phacoemulsification with PPV and SO) and significant corneal opacity will be excluded. If any significant post-PPV complication develops, patient will be excluded from the study.